Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Valutazione della sicurezza e dell'efficacia a lungo termine di Lunsekimig (SAR443765) in partecipanti adulti con asma da moderato a grave. (AIRPHRODITE)

16 novembre 2026 aggiornato da: Sanofi

Uno studio di estensione in aperto per valutare la sicurezza e l'efficacia a lungo termine di lunsekimig sottocutaneo in partecipanti adulti con asma da moderato a grave che hanno partecipato allo studio DRI16762

This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.

The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.

Panoramica dello studio

Stato

Iscrizione su invito

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

900

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Buenos Aires, Argentina, 1121
        • Investigational Site Number : 0320005
      • Buenos Aires, Argentina, 1414
        • Investigational Site Number : 0320004
      • Buenos Aires, Argentina, 1122
        • Investigational Site Number : 0320012
      • Buenos Aires, Argentina, 1425
        • Investigational Site Number : 0320011
      • Mendoza, Argentina, 5500
        • Investigational Site Number : 0320009
      • Mendoza, Argentina, 5500
        • Investigational Site Number : 0320015
      • Santa Fe, Argentina, 3000
        • Investigational Site Number : 0320010
    • Buenos Aires
      • Berazategui, Buenos Aires, Argentina, 1886
        • Investigational Site Number : 0320007
      • La Plata, Buenos Aires, Buenos Aires, Argentina, B1904CUL
        • Investigational Site Number : 0320003
      • Lobos, Buenos Aires, Argentina, 7240
        • Investigational Site Number : 0320013
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320002
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320006
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320020
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
        • Investigational Site Number : 0320008
      • Mechelen, Belgio, 2800
        • Investigational Site Number : 0560002
      • Rio de Janeiro, Brasile, 22241-180
        • CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
      • São Paulo, Brasile, 05403-000
        • Incor - Instituto do Coracao- Site Number : 0760011
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasile, 40060-330
        • Associacao Proar- Site Number : 0760003
    • Goiás
      • Goiânia, Goiás, Brasile, 74605-020
        • Universidade Federal de Goias- Site Number : 0760007
    • Paraná
      • Curitiba, Paraná, Brasile, 80030-110
        • CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
    • Pernambuco
      • Recife, Pernambuco, Brasile, 50070-550
        • Instituto de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasile, 90610-000
        • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
    • Santa Catarina
      • Blumenau, Santa Catarina, Brasile, 89030-101
        • Hospital Dia do Pulmão- Site Number : 0760005
    • Ontario
      • Ajax, Ontario, Canada, L1S 2J5
        • Investigational Site Number : 1240013
      • Hamilton, Ontario, Canada, L8N 4A6
        • Investigational Site Number : 1240003
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Investigational Site Number : 1240004
      • Trois-Rivières, Quebec, Canada, G8T 7A1
        • Investigational Site Number : 1240001
    • Biobio
      • Concepción, Biobio, Chile, 4070094
        • Investigational Site Number : 1520013
    • Maule Region
      • Talca, Maule Region, Chile, 3465584
        • Investigational Site Number : 1520001
    • Reg Metropolitana de Santiago
      • Recoleta, Reg Metropolitana de Santiago, Chile, 8420000
        • Investigational Site Number : 1520015
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500587
        • Investigational Site Number : 1520006
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500692
        • Investigational Site Number : 1520005
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500698
        • Investigational Site Number : 1520004
      • Santiago, Reg Metropolitana de Santiago, Chile, 7750495
        • Investigational Site Number : 1520002
    • Valparaiso
      • Quillota, Valparaiso, Chile, 2260877
        • Investigational Site Number : 1520008
      • Viña del Mar, Valparaiso, Chile, 2531172
        • Investigational Site Number : 1520011
      • Viña del Mar, Valparaiso, Chile, 2540364
        • Investigational Site Number : 1520012
      • Beijing, Cina, 100144
        • Investigational Site Number : 1560011
      • Changchun, Cina, 130021
        • Investigational Site Number : 1560010
      • Changsha, Cina, 410015
        • Investigational Site Number : 1560017
      • Chengde, Cina, 067020
        • Investigational Site Number : 1560021
      • Guangzhou, Cina, 510150
        • Investigational Site Number : 1560009
      • Guangzhou, Cina, 510000
        • Investigational Site Number : 1560053
      • Guangzhou, Cina, 510163
        • Investigational Site Number : 1560001
      • Guiyang, Cina, 550002
        • Investigational Site Number : 1560037
      • Hefei, Cina, 230032
        • Investigational Site Number : 1560006
      • Hohhot, Cina, 010050
        • Investigational Site Number : 1560014
      • Lanzhou, Cina, 730000
        • Investigational Site Number : 1560030
      • Nanchang, Cina, 330006
        • Investigational Site Number : 1560007
      • Pingxiang, Cina, 337055
        • Investigational Site Number : 1560002
      • Shanghai, Cina, 200433
        • Investigational Site Number : 1560013
      • Shenyang, Cina, 110004
        • Investigational Site Number : 1560015
      • Taiyuan, Cina, 030001
        • Investigational Site Number : 1560057
      • Tianjin, Cina, 300211
        • Investigational Site Number : 1560055
      • Wenzhou, Cina, 325027
        • Investigational Site Number : 1560005
      • Wuhan, Cina, 430030
        • Investigational Site Number : 1560003
      • Wuhan, Cina, 430030
        • Investigational Site Number : 1560022
      • Xuzhou, Cina, 221006
        • Investigational Site Number : 1560004
      • Yangzhou, Cina, 225000
        • Investigational Site Number : 1560016
      • Zhanjiang, Cina, 524004
        • Investigational Site Number : 1560012
    • Seoul-teukbyeolsi
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 03722
        • Investigational Site Number : 4100001
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 03080
        • Investigational Site Number : 4100002
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 05030
        • Investigational Site Number : 4100004
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 05505
        • Investigational Site Number : 4100006
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 06351
        • Investigational Site Number : 4100005
      • Leipzig, Germania, 04347
        • Investigational Site Number : 2760001
      • Mainz, Germania, 55128
        • Investigational Site Number : 2760005
      • Fukushima, Giappone, 960-1295
        • Investigational Site Number : 3920008
      • Kyoto, Giappone, 610-0113
        • Investigational Site Number : 3920006
      • Kyoto, Giappone, 612-8555
        • Investigational Site Number : 3920009
      • Miyazaki, Giappone, 889-1692
        • Investigational Site Number : 3920012
    • Kagawa-ken
      • Sakaidechō, Kagawa-ken, Giappone, 762-8550
        • Investigational Site Number : 3920002
    • Tokyo
      • Chūō, Tokyo, Giappone, 104-0031
        • Investigational Site Number : 3920011
    • Yamaguchi
      • Ube, Yamaguchi, Giappone, 755-8505
        • Investigational Site Number : 3920005
      • Calicut, India, 673008
        • Investigational Site Number : 3560007
      • Hyderabad, India, 500084
        • Investigational Site Number : 3560009
      • Kanpur, India, 208001
        • Investigational Site Number : 3560008
      • Nagpur, India, 441203
        • Investigational Site Number : 3560001
      • Pune, India, 411057
        • Investigational Site Number : 3560004
      • Ashkelon, Israele, 7830604
        • Investigational Site Number : 3760006
      • Haifa, Israele, 3104802
        • Investigational Site Number : 3760001
      • Haifa, Israele, 3436212
        • Investigational Site Number : 3760008
      • Jerusalem, Israele, 9103102
        • Investigational Site Number : 3760003
      • Jerusalem, Israele, 9112001
        • Investigational Site Number : 3760002
      • Petah Tikva, Israele, 4941492
        • Investigational Site Number : 3760010
      • Rehovot, Israele, 7610001
        • Investigational Site Number : 3760004
      • Tel Aviv, Israele, 6423906
        • Investigational Site Number : 3760007
    • Roma
      • Rome, Roma, Italia, 00168
        • Investigational Site Number : 3800010
      • Chihuahua City, Messico, 31000
        • Investigational Site Number : 4840002
      • Durango, Messico, 34000
        • Investigational Site Number : 4840003
      • Veracruz, Messico, 91900
        • Investigational Site Number : 4840008
    • Nuevo León
      • Monterrey, Nuevo León, Messico, 66465
        • Investigational Site Number : 4840004
    • Querétaro
      • San Juan del Río, Querétaro, Messico, 76800
        • Investigational Site Number : 4840005
    • Yucatán
      • Mérida, Yucatán, Messico, 97070
        • Investigational Site Number : 4840007
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polonia, 60-693
        • Investigational Site Number : 6160001
    • Świętokrzyskie Voivodeship
      • Chęciny, Świętokrzyskie Voivodeship, Polonia, 26-060
        • Investigational Site Number : 6160004
      • Bradford, Regno Unito, BD9 6DA
        • Investigational Site Number : 8260008
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Regno Unito, CB2 2QQ
        • Investigational Site Number : 8260001
    • Glasgow City
      • Glasgow, Glasgow City, Regno Unito, G12 0YN
        • Investigational Site Number : 8260004
    • London, City of
      • London, London, City of, Regno Unito, W1G 8HU
        • Investigational Site Number : 8260011
    • Surrey
      • Chertsey, Surrey, Regno Unito, KT16 0PZ
        • Investigational Site Number : 8260005
      • Madrid, Spagna, 28007
        • Investigational Site Number : 7240008
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], Spagna, 08017
        • Investigational Site Number : 7240009
    • Madrid, Comunidad de
      • Chamberí, Madrid, Comunidad de, Spagna, 28010
        • Investigational Site Number : 7240011
    • Arizona
      • Chandler, Arizona, Stati Uniti, 85224
        • Chandler Clinical Research Trials- Site Number : 8400075
      • Tucson, Arizona, Stati Uniti, 85712
        • Tucson Clinical Research Institute- Site Number : 8400085
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80014
        • Allianz Research Institute - Aurora- Site Number : 8400026
      • Wheat Ridge, Colorado, Stati Uniti, 80033
        • Western States Clinical Research- Site Number : 8400014
    • Florida
      • Boynton Beach, Florida, Stati Uniti, 33435
        • Helix Biomedics- Site Number : 8400114
      • Cutler Bay, Florida, Stati Uniti, 33157
        • Beautiful Minds Clinical Research Center- Site Number : 8400049
      • Hialeah, Florida, Stati Uniti, 33010
        • Qway Research - Hialeah- Site Number : 8400015
      • Kissimmee, Florida, Stati Uniti, 34744
        • Ilumina Medical Research- Site Number : 8400095
      • Miami, Florida, Stati Uniti, 33184
        • High Quality Research- Site Number : 8400039
      • Miami, Florida, Stati Uniti, 33186
        • Innovations Biotech- Site Number : 8400040
      • Miami, Florida, Stati Uniti, 33186
        • New Access Medical Center- Site Number : 8400043
      • Miami, Florida, Stati Uniti, 33135
        • Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048
      • Miami Lakes, Florida, Stati Uniti, 33014
        • Deluxe Health Center- Site Number : 8400045
      • Pembroke Pines, Florida, Stati Uniti, 33025
        • Tellabio International Research Services- Site Number : 8400083
      • Pembroke Pines, Florida, Stati Uniti, 33029
        • Alfa Medical Research LLC- Site Number : 8400146
      • Pensacola, Florida, Stati Uniti, 32503
        • Avanza Medical Research Center- Site Number : 8400135
      • Sarasota, Florida, Stati Uniti, 34239
        • Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
    • Georgia
      • Cordele, Georgia, Stati Uniti, 31015
        • Private Practice - Dr. David Kavtaradze- Site Number : 8400081
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02115
        • Brigham & Women's Hospital- Site Number : 8400034
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63141
        • Midwest Clinical Research Center - St. Louis- Site Number : 8400006
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28287
        • Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
    • Ohio
      • Toledo, Ohio, Stati Uniti, 43617
        • Asthma & Allergy Center - Toledo- Site Number : 8400017
    • Oklahoma
      • Edmond, Oklahoma, Stati Uniti, 73034
        • OK Clinical Research- Site Number : 8400021
    • Pennsylvania
      • DuBois, Pennsylvania, Stati Uniti, 15801
        • Clinical Research Associates of Central Pennsylvania- Site Number : 8400116
      • Pittsburgh, Pennsylvania, Stati Uniti, 15241
        • Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
    • Texas
      • Austin, Texas, Stati Uniti, 78759
        • Orion Clinical Research- Site Number : 8400001
      • Boerne, Texas, Stati Uniti, 78006
        • South Texas Medical Research Institute - TTS Research- Site Number : 8400010
      • Dallas, Texas, Stati Uniti, 75246
        • Baylor University Medical Center- Site Number : 8400002
      • El Paso, Texas, Stati Uniti, 79903
        • Western Sky Medical Research- Site Number : 8400023
      • McKinney, Texas, Stati Uniti, 75069
        • Metroplex Pulmonary and Sleep Center- Site Number : 8400022
      • Benoni, Sud Africa, 1500
        • Investigational Site Number : 7100004
      • Benoni, Sud Africa, 1500
        • Investigational Site Number : 7100005
      • Cape Town, Sud Africa, 7530
        • Investigational Site Number : 7100003
      • Cape Town, Sud Africa, 7700
        • Investigational Site Number : 7100002
      • Durban, Sud Africa, 4001
        • Investigational Site Number : 7100001
      • Pretoria, Sud Africa, 0157
        • Investigational Site Number : 7100006
      • Taipei, Taiwan, 110
        • Investigational Site Number : 1580003
      • Bursa, Turchia (Türkiye), 16059
        • Investigational Site Number : 7920006
      • Istanbul, Turchia (Türkiye), 34098
        • Investigational Site Number : 7920002
      • Istanbul, Turchia (Türkiye), 34854
        • Investigational Site Number : 7920003
      • Kayseri, Turchia (Türkiye), 38039
        • Investigational Site Number : 7920007
      • Kirikkale, Turchia (Türkiye), 71100
        • Investigational Site Number : 7920008
      • Mersin, Turchia (Türkiye), 33070
        • Investigational Site Number : 7920001
      • İzmit, Turchia (Türkiye), 41001
        • Investigational Site Number : 7920005
      • Mosonmagyaróvár, Ungheria, 9200
        • Investigational Site Number : 3480004

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol

  • Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:

    • For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone
    • For Study ACT18301: LABA with or without LTRA
  • Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures

  • Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:

For female participants:

  • incapable of becoming pregnant, or
  • not pregnant or breast feeding
  • no eggs donation or cryopreserving eggs

For male participants:

-- No sperm donation or cryopreserving sperm

- Capable of giving signed informed consent

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
  • Participant who was diagnosed with a new pulmonary disease which may impair lung function
  • Current smoker or active vaping of any products and/or marijuana smoking
  • Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Participants who are receiving prohibited concomitant medications
  • Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Lunsekimig

Participants will receive subcutaneous injection of lunsekimig according to established dosing interval

  • Pharmaceutical form: Solution for injection in vial or pre-filled syringe (PFS)
  • Route of administration: Subcutaneous injection
Altri nomi:
  • SAR443765

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Lasso di tempo: From study baseline to week 148

Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year.

From study baseline to week 148

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Annualized rate of asthma exacerbation events
Lasso di tempo: From study baseline to weeks 48, 96 and 144
From study baseline to weeks 48, 96 and 144
Change from parent study baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Lasso di tempo: From parent study baseline to weeks 48, 96 and 144
From parent study baseline to weeks 48, 96 and 144
Serum lunsekimig concentrations
Lasso di tempo: From study baseline to week 144
From study baseline to week 144
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Lasso di tempo: From study baseline to week 144
From study baseline to week 144
Change from parent study baseline in Asthma Control Questionnaire5 (ACQ-5) score
Lasso di tempo: From parent study baseline to weeks 48, 96 and 144

The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.

From parent study baseline to weeks 48, 96 and 144
Proportion of participants with ≥0.5-point reduction in each ACQ-5 score as compared to parent study baseline score
Lasso di tempo: From parent study baseline to weeks 48, 96 and 144

Defined as ACQ-5 responder analysis

From parent study baseline to weeks 48, 96 and 144
Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores
Lasso di tempo: From parent study baseline to weeks 48, 96 and 144

The AQLQ(S) + 12 was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life.

From parent study baseline to weeks 48, 96 and 144

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 settembre 2024

Completamento primario (Stimato)

20 gennaio 2031

Completamento dello studio (Stimato)

20 gennaio 2031

Date di iscrizione allo studio

Primo inviato

20 settembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

20 settembre 2024

Primo Inserito (Effettivo)

24 settembre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • LTS17231
  • 2025-522896-27 (Identificatore di registro: CTIS)
  • U1111-1303-3645 (Identificatore di registro: ICTRP)
  • 2025 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .